Lantheus (LNTH) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lantheus (LNTH) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 93.2% versus a loss of 42.7%. Over five years, LNTH leads with a +330.7% price change compared with -91.0% for NTLA. Lantheus is the larger company by market cap ($6.54 billion vs $1.64 billion), about 4.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | NTLA |
|---|---|---|
| Share price | $100.18 | $11.71 |
| Market cap | $6.54B | $1.64B |
| 1-day change | +0.23% | -5.34% |
| YTD return | +50.53% | +30.26% |
| 1-year return | +93.25% | -42.71% |
| 5-year return | +330.70% | -91.03% |
| P/E ratio (TTM) | 24.26 | — |
| Forward P/E | 15.71 | — |
| EPS (TTM) | $4.13 | $-3.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | — |
| Revenue growth (YoY) | +0.50% | — |
| Net income (latest FY) | $233.56M | — |
| Gross margin | 61.10% | — |
| Operating margin | 20.16% | — |
| Net margin | 15.15% | — |
| 52-week high | $111.86 | $28.25 |
| 52-week low | $50.16 | $7.95 |
| Distance from 52-week high | -10.44% | -58.55% |
| Analyst consensus | none | buy |
| Avg. price target upside | +7.55% | +97.35% |
| Average volume | 1.34M | 4.09M |
| Shares outstanding | 65.30M | 140.13M |
| Employees | 1,193 | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 4.0 times larger than Intellia Therapeutics by market value ($6.54B vs $1.64B).
- LNTH has outperformed NTLA by 136.0 percentage points over the past year.
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
LNTH vs NTLA FAQ
Which is bigger, Lantheus or Intellia Therapeutics?
Lantheus (LNTH) is larger, with a market capitalization of $6.54B compared with $1.64B for Intellia Therapeutics (NTLA).
Which stock has performed better over the past year, LNTH or NTLA?
LNTH returned +93.25% over the past 12 months, compared with -42.71% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.